Semaglutide to Limit Weight Gain After Quitting Smoking

Trial details

Who runs it

The University of Texas Health Science Center, Houston

Trial code

NCT06173778

Record updated

21 September 2026

Original description

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.Read full original descriptionShow less

A Randomized Controlled Trial of Once-Weekly Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight/Obesity

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

Inclusion: Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study; Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea; Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test; Desire to quit smoking (defined as "intend to quit within one month"); Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy); Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization; Normal cognitive restraint (assessed as cognitive restraint score of <4 from the Three Factor Eating Habits Questionnaire); Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator.

Exclusion: Acute pancreatitis within the past 6 months prior to screening; Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 60 days prior to screening; Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months prior to screening (existing diagnosis or as determined by the structured interview); Urine drug test positive, before randomization, for any of the following substances:; benzodiazepines; cocaine; opioids; amphetamines; methamphetamine; buprenorphine; barbiturates; 3,4-methylenedioxy-methamphetamine (MDMA); Tetrahydrocannabinol (THC); Previously undergone bariatric surgery; Gained/lost ≥4.5 kg over the past 6 months (prior to screening); Uncontrolled thyroid disease (the criterion will be assessed at the Study Physician's and the Principal Investigator's discretion); Smoking-Related Exclusions; -Currently using other combustible (e.g., cigars), other (e.g., chewing tobacco, snuff, snus) or alternative (e.g., electronic cigarettes) tobacco products; Medication-Related Exclusions; Currently using pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion); Currently or recently (last 90 days prior to screening) taking medication used for weight management (i.e., orlistat, lorcaserin,vi naltrexone-bupropion, liraglutide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine); Currently or recently (within the past 14 days prior to screening) taking medication(s) known to impact appetite and/or weight (i.e., corticosteroids, excluding inhaled); General Exclusions; Surgery scheduled for the duration of the trial, except for minor surgical procedures, in opinion of the Principal Investigator and/or the Study Physician; Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2); History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed; Severe gastrointestinal disease (i.e., severe gastroparesis); Known or suspected hypersensitivity to nicotine/nicotine patches; semaglutide, excipients, or related products; Have any illness or condition which in the opinion of the Principal Investigator and/or the Study Physician would preclude safe and/or successful completion of the study; Psychiatric / Substance Use Exclusions; Psychotic or bipolar disorder, or mood disorder with psychotic features; or eating disorder (existing clinical diagnosis or as determined by the structured interview); Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C ≥48 mmol/mol (6.5%) as measured by central laboratory at screening); End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR < 15 ml/min/1.73 m2 as measured by central laboratory at screening); Currently using oral or injectable glucose lowering medications; Medical Exclusions; History or presence of chronic pancreatitis; Systolic blood pressure (SBP) >159 mmHg and/or diastolic blood pressure (DBP) >99 mmHg); Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception; Moderate to high risk for suicidality (as determined by the structured interview); Weight-Related Exclusions; Currently enrolled in a behavioral weight management plan; Current, anticipated, or pending enrollment in another research study during this trial that could potentially affect participant safety and/or the study data/design as determined by the Principal Investigator and/or Study Physician; Not planning to live in the area for the duration of this trial; Unable to communicate (read, write, and speak) fluently in English.

ClinicalTrials.gov NCT06173778